* Says Distributor has entered into an agreement with distributor of veterinary products, Henry Schein Source text for Eikon: Further company coverage: (email@example.com; +48 58 698 3920)
interested parties in gaining access to the high-value implant market. We note that Dentsply and even the distributor Henry Schein have recently utilized acquisitions to enhance their capabilities and market share.
though management suggested new customer sales for the CEREC platform and other equipment remained strong. In light of Henry Schein ’s recent strong performance in this category, it appears Patterson is yielding some ground it gained over the last
long-term shareholder interests. Henry Schein distributes health care products ..... operating and financial risk at Henry Schein is limited. Schein's scale helps ..... maintaining our fair value estimate for Henry Schein at $105 per share, which implies
Henry Schein 's performance continues to track our expectations. The company posted 9.8% non-GAAP earnings per share growth, helped
Henry Schein (NASDAQ: HSIC ) Q2 results : Net Sales: $2,615.4M (+9.3%); Gross Profit: $728.5M (+8.7%); Operating Income
Henry Schein (NASDAQ: HSIC ): Q2 EPS of $1.35 beats by $0.01 . Revenue of $2.62B (+9.6% Y/Y) beats by $60M . Press Release Post your comment!
We found the 4.7% decline in dental equipment sales particularly surprising this quarter, which, in light of Henry Schein ’s recent gains in this market, suggests Patterson is losing market share. We speculate Patterson’s CEREC CAD
This year’s harsh winter had an expected cooling effect on Henry Schein ’s performance during the company’s first quarter. Management estimates that the negative weather effect depressed total
We’re leaving our $105 fair value estimate and wide moat rating for Henry Schein unchanged after the company’s fourth-quarter results met our expectations. Excluding seasonal differences from the flu and